BMS-433771 free base
| Code | Size | Price |
|---|
| TAR-T26848-5mg | 5mg | £483.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T26848-50mg | 50mg | £1,235.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T26848-100mg | 100mg | £1,934.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
BMS-433771, a novel inhibitor of respiratory syncytial virus (RSV), binds the RSV F glycoprotein and inhibits membrane fusion.
CAS:
543700-68-1
Formula:
C21H23N5O2
Molecular Weight:
377.448
Purity:
0.98
SMILES:
OCCCCn1c(Cn2c3cnccc3n(C3CC3)c2=O)nc2ccccc12
References
1. Haid S, Grethe C, Bankwitz D, Grunwald T, Pietschmann T. Identification of a Human Respiratory Syncytial Virus Cell Entry Inhibitor by Using a Novel Lentiviral Pseudotype System. J Virol. 2015 Dec 30;90(6):3065-73. doi: 10.1128/JVI.03074-15. PubMed PMID: 26719246; PubMed Central PMCID: PMC4810627.
2. Ji D, Ye W, Chen H. Revealing the binding mode between respiratory syncytial virus fusion protein and benzimidazole-based inhibitors. Mol Biosyst. 2015 Jul;11(7):1857-66. doi: 10.1039/c5mb00036j. PubMed PMID: 25872614.
3. Magro M, Andreu D, G?mez-Puertas P, Melero JA, Palomo C. Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein. J Virol. 2010 Aug;84(16):7970-82. doi: 10.1128/JVI.00447-10. Epub 2010 Jun 9. PubMed PMID: 20534864; PubMed Central PMCID: PMC2916552.
4. Sin N, Venables BL, Combrink KD, Gulgeze HB, Yu KL, Civiello RL, Thuring J, Wang XA, Yang Z, Zadjura L, Marino A, Kadow KF, Cianci CW, Clarke J, Genovesi EV, Medina I, Lamb L, Krystal M, Meanwell NA. Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4857-62. doi: 10.1016/j.bmcl.2009.06.030. Epub 2009 Jun 13. PubMed PMID: 19596574.